Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Institutions of which they are part Head of group Head and Neck Cancer: Biomedical Research Cancer Stem cells Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Matilde Lleonart Pajarin LinkedIn Twitter Orcid Email Institutions of which they are part Head of group Head and Neck Cancer: Biomedical Research Cancer Stem cells Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Research lines Estudio de proteínas de unión a RNA como nuevos factores pronóstico y diagnóstico en cáncer En nuestro laboratorio hemos efectuado diversos “screenings” genéticos para detectar nuevos genes implicados en proliferación celular in vitro que además poséan un papel relevante en cáncer humano. De entre ellos descubrimos la proteínas CIRP, la cual hemos descrito como proteína oncogénica. Actualmente estamos valorando la función de CIRP en diversos tipos tumorales en correlación con la evolución clínica de los pacientes. IP: Matilde Lleonart Pajarin Pagination First page « Previous page ‹ Page 1 Current page 2 Projects New compounds targeting head and neck cancer as Trojan horses against chemoresistant cells IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea, Marina Bataller Fernández, Gabriela Isabel Fuentes Llopis, Almudena Sanchez Garcia Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 20000 Reference: 2023 LLAV 00102 Duration: 01/02/2024 - 31/07/2024 Therapeutical approaches against chemoresistant cancers IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea, Fco. Xavier De la Cruz Montserrat, Juan Lorente Guerrero, Natalia Padilla Sirera, Marina Bataller Fernández, Almudena Sanchez Garcia, Selen Ozkan Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 01205 Duration: 01/01/2022 - 30/06/2025 Ayudas Margarita Salas IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea, Judit Álvarez González Funding agency: Ministerio de Universidades Funding: 0.01 Reference: MIU/M_SALAS/2021/GARCIA_UB Duration: 01/04/2022 - 31/03/2022 Novel terapéutic approaches against COVID-19 IP: Matilde Lleonart Pajarin Collaborators: Marina Bataller Fernández, Almudena Sanchez Garcia, Yoelsis Garcia Mayea Funding agency: Fundació La Marató de TV3 Funding: 161875 Reference: 202116 Duration: 23/09/2021 - 22/09/2024 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 … Next page › Last page »
